These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29067309)

  • 21. Who funds Alzheimer's disease drug development?
    Cummings J; Bauzon J; Lee G
    Alzheimers Dement (N Y); 2021; 7(1):e12185. PubMed ID: 34095442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug development in Alzheimer's disease: the path to 2025.
    Cummings J; Aisen PS; DuBois B; Frölich L; Jack CR; Jones RW; Morris JC; Raskin J; Dowsett SA; Scheltens P
    Alzheimers Res Ther; 2016 Sep; 8():39. PubMed ID: 27646601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
    Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Drug Research and Development for Alzheimer's Pathology: Present and Prospect.
    Wang T
    Shanghai Arch Psychiatry; 2017 Aug; 29(4):237-239. PubMed ID: 28955143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of Disease-modifying Therapy for Alzheimer's Disease].
    Akiyama H
    Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease.
    Canevelli M; Remoli G; Bacigalupo I; Valletta M; Toccaceli Blasi M; Sciancalepore F; Bruno G; Cesari M; Vanacore N
    J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32722106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solanezumab for Alzheimer's disease.
    Samadi H; Sultzer D
    Expert Opin Biol Ther; 2011 Jun; 11(6):787-98. PubMed ID: 21504387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion.
    Frank A; Ismail Z; Wilson M; Gauthier S; Verret L; Hsiung GR; Borrie M
    Can J Neurol Sci; 2023 Dec; ():1-9. PubMed ID: 38052729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics.
    Ritter A; Cummings J
    Front Neurol; 2015; 6():186. PubMed ID: 26379620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.